Teva Pharmaceutical Industries Ltd Stock: price and insider trades · United States

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company listed on the NYSE/NASDAQ and closely tied to the U.S. market, while remaining headquartered in Israel. The company was incorporated in Israel on February 13, 1944, with roots tracing back to a predecessor established in 1901. For investors, Teva is best understood as a hybrid healthcare group: it combines a large generics franchise with biosimilars, over-the-counter products and a focused portfolio of innovative medicines. Its broader portfolio also includes certain distribution, API and contract manufacturing activities, although management has stated that the API business is held for sale as part of the company’s strategic reshaping. ([sec.gov](https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm?utm_source=openai))

Operationally, Teva runs its business across three main geographic segments: the United States, Europe and International Markets. That structure allows the company to manage its full product portfolio regionally, from generics and biosimilars to branded innovative medicines. Teva says it employs about 37,000 people and operates in 57 markets, underscoring a broad commercial and manufacturing footprint. In competitive terms, Teva remains one of the world’s leading generic-drug companies and a major player in complex generics and biosimilars, with a particularly strong strategic presence in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/818686/000119312525125044/d830217d424b5.htm?utm_source=openai))